Skip to main content
PepStack

Erythropoietin

Pituitary & Trophic Hormones
EPOEpoetinProcritEpogenAranesp

Overview

Erythropoietin (EPO) is a glycoprotein hormone that is primarily produced by the kidneys in response to hypoxia, although it can also be synthesized in the liver. It belongs to the class of pituitary and trophic hormones and plays a crucial role in the regulation of red blood cell production. Synthetic forms of erythropoietin, such as epoetin alfa, are used in clinical settings to treat anemia, particularly in chronic kidney disease and cancer patients undergoing chemotherapy. Researchers have extensively studied both endogenous and synthetic erythropoietin for their physiological and therapeutic roles. The primary physiological role of erythropoietin is to stimulate erythropoiesis, the process of red blood cell production in the bone marrow. It is crucial for maintaining adequate oxygen-carrying capacity in the blood. Research has also explored its potential neuroprotective and cardioprotective effects, although these areas require further investigation. Erythropoietin exerts its effects by binding to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow. This binding activates the JAK2/STAT5 signaling pathway, leading to the proliferation and differentiation of these progenitor cells into mature red blood cells. Researchers have observed that this mechanism is critical for the hormone's erythropoietic function. The pharmacokinetics of erythropoietin vary between its endogenous and synthetic forms. Endogenous erythropoietin has a circulating half-life of approximately 5-9 hours. Synthetic forms, such as epoetin alfa, have a longer half-life, particularly when administered subcutaneously. The metabolism primarily occurs in the liver, and the hormone is excreted by the kidneys. Clinically, erythropoietin is used to treat anemia associated with chronic kidney disease, chemotherapy, and certain other conditions. It is approved by regulatory agencies such as the FDA and EMA for these uses. However, its use is carefully regulated due to potential risks, including thromboembolic events. Researchers continue to explore its broader therapeutic potential while adhering to regulatory guidelines.

Mechanism of Action

Erythropoietin acts on erythropoietin receptors (EPOR) located on erythroid progenitor cells in the bone marrow. Upon binding, it activates the JAK2/STAT5 signaling pathway, which promotes the proliferation and differentiation of these progenitor cells into mature red blood cells.

Molecular Data

FormulaC42H73NO16
Molecular Weight848 g/mol
CAS Number113427-24-0
PubChem CID92043599

Half-Life & Pharmacokinetics

EndogenousCirculating half-life ~5-9 hours
Subcutaneous~24-48 hours
Intravenous~4-13 hours

Synthetic forms like epoetin alfa have longer half-lives when administered subcutaneously compared to intravenously.

Storage

Temperature

Refrigerate at 2-8°C

Light

Protect from light

Form

Aqueous solution: use within specified time after opening

Notes

Do not freeze; discard if frozen.

Solubility

Erythropoietin is soluble in water, which is relevant for its formulation as an injectable solution.

Legal Status

🇩🇪DE

Verschreibungspflichtig (prescription only); not a controlled substance under BtMG.

🇺🇸US

FDA approved for anemia treatment; prescription required.

🇦🇺AU

TGA Schedule 4 (prescription only medicine).

🇬🇧UK

Prescription only medicine (POM) under MHRA regulations.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

8 Research Publications

Erythropoietin in tumor angiogenesis.

Review

Experimental cell research · 2019

Researchers observed that erythropoietin (EPO), a protein known for regulating red blood cell production, also plays a role in tumor growth by promoting the formation of new blood vessels. They highlighted the complex effects of EPO on tumors and suggested that understanding its different forms could lead to targeted treatments that minimize side effects.

  • EPO is involved in both normal blood cell production and tumor blood vessel formation.
  • The mechanisms by which EPO promotes tumor growth are not fully understood.
  • Targeting specific EPO pathways may help develop safer cancer treatments.
PubMed

Erythropoietin and Nonhematopoietic Effects.

Review

The American journal of the medical sciences · 2017

Researchers found that erythropoietin (EPO), known for its role in red blood cell production, also has protective effects on various organs like the brain and heart. They observed that EPO can help tissues recover from injuries and may have new potential uses beyond treating anemia.

  • EPO receptors are present in organs beyond the blood system.
  • EPO helps protect tissues from damage during stress.
  • EPO may improve recovery after injuries.
PubMed

Erythropoietin.

Review

Frontiers of hormone research · 2016

Researchers observed that erythropoietin (Epo) is crucial for red blood cell production, which affects athletic performance. They noted that while Epo can be misused by athletes, detection methods are improving, especially with the introduction of the Athlete Biological Passport to monitor changes in blood parameters.

  • Epo promotes red blood cell production, impacting aerobic power.
  • Athletes may misuse Epo, but it can be detected through chemical tests.
  • The Athlete Biological Passport helps monitor athletes for blood doping.
PubMed

[Erythropoietin and neuroprotection].

Review

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 2010

Researchers found that erythropoietin (Epo), known for treating anemia, also plays a crucial role in brain development and protection. They observed that Epo can stimulate brain cell growth in response to low oxygen levels and may help reduce brain damage in infants experiencing hypoxia-ischemia.

  • Epo is important for brain development and neuroprotection.
  • Epo stimulates brain cell growth during low oxygen conditions.
  • Epo may reduce brain damage in infants with hypoxia-ischemia.
PubMed

Erythropoietin and analogs.

Review

Handbook of experimental pharmacology · 2010

Researchers observed that erythropoietin (EPO) is a hormone that boosts red blood cell production, enhancing oxygen delivery in the body. This has led to its ban in sports due to doping concerns, especially in endurance events. The study highlights the challenges in detecting various forms of EPO used in doping and discusses methods for identifying these substances.

  • EPO increases red blood cell growth and oxygenation.
  • Recombinant EPO has been widely abused in sports since 1990.
  • New detection methods are needed for different EPO analogs.
PubMed

Erythropoietin pharmacology.

Review

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2007

Researchers observed that recombinant human erythropoietin (rHuEPO) can effectively treat anemia in cancer patients undergoing chemotherapy, particularly when hemoglobin levels drop below 10 g/dl. They noted that subcutaneous administration of rHuEPO offers advantages over intravenous use, including better bioavailability and longer-lasting effects.

  • rHuEPO is an alternative to blood transfusions for treating chemotherapy-induced anemia.
  • Subcutaneous administration of rHuEPO has better bioavailability and a longer half-life.
  • Serious side effects include hypertension and increased risk of blood clots.
PubMed

[Overview of erythropoietin].

Review

Nephrologie · 1991

Researchers found that erythropoietin (Epo) is a protein mainly produced in the kidneys that helps create red blood cells. They observed that Epo production increases when oxygen levels are low, and while the Epo receptor structure is not fully understood, recombinant Epo is effectively used to treat patients with kidney diseases.

  • Epo is primarily produced in the kidneys and to a lesser extent in the liver.
  • Epo production is stimulated by low oxygen levels in the body.
  • Recombinant Epo has been successfully used to treat kidney disease patients.
PubMed

Epoetin: human recombinant erythropoietin.

Review

Clinical pharmacy · 1989

Researchers found that epoetin, a synthetic form of erythropoietin, effectively treats anemia in patients with chronic kidney failure. It helps increase red blood cell production, reducing the need for blood transfusions and improving patients' quality of life. However, it may cause side effects like high blood pressure and flu-like symptoms.

  • Epoetin is effective in treating anemia related to chronic kidney failure.
  • It can improve quality of life and reduce the need for blood transfusions.
  • Common side effects include high blood pressure and flu-like symptoms.
PubMed

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

This page is for informational and research purposes only. All information is based on published scientific literature. Nothing on this page constitutes medical advice or replaces consultation with a qualified healthcare professional.